Oppenheimer analyst Matthew Biegler maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $16.00. The company’s shares closed yesterday at $10.18.
Biegler covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Arvinas Holding Company, and Nurix Therapeutics. According to TipRanks, Biegler has an average return of 3.9% and a 39.62% success rate on recommended stocks.
Currently, the analyst consensus on Fulcrum Therapeutics is a Strong Buy with an average price target of $13.00, which is a 27.70% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.97 and a one-year low of $2.25. Currently, Fulcrum Therapeutics has an average volume of 621.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulcrum Therapeutics (FULC) Company Description:
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
- Fulcrum Therapeutics expects cash to fund operations into 2026
- Fulcrum Therapeutics reports Q4 EPS (40c), consensus (43c)
- Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet
- Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
